About 90 percent of people fully inoculated by the Pfizer-BioNTech vaccine are well protected from variants of the novel ...
Hosted on MSN
Pfizer’s New Study on Zavegepant: A Potential Game-Changer for Pediatric Migraine Treatment
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.
Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic ...
New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results